tbuckley/cabot-search huggingface dataset:
Clinical and laboratory aspects of raised virus antibody titres in systemic lupus erythematosus.
Authors: N F Rothfield, A S Evans, J C Niederman
Journal: Annals of the Rheumatic Diseases (1973)

A possible role of virus infection in the pathogenesis of systemic lupus erythematosus (SLE) has been postulated.This concept has been supported by the demonstration by Mellors, Shirai, Aoki, Huebner, and Krawczynski (1971) and Levy and Pincus (1970) of a role of virus infection in the disease of New Zealand mice (NZB) which is a model of SLE (Howie and Helyer, 1968); by reports of microtubular struc- tures in glomerular endothelium from SLE patients (Fresco, 1968; Grausz, Earley, Stephens, Lee, and Hopper, 1970; and Norton, 1969) and by the occur- rence of high antibody titres to measles, rubella, and parainfluenza 1 viruses (Phillips and Christian, 1970; Hurd, Dowdle, Casey, and Ziff, 1972; Hollinger, Sharp, Lidsky, and Rawls, 1971; Feltkamp, van Loghem, Lucas, van der Noordaa, de Rooy, and ten Veen, 1971) in SLE patients as compared to controls.High antibody titres to the Epstein-Barr (EB) virus have also been reported by Dalldorf, Carvalho, Jamra, Frost, Erlich, and Marigo (1969), and in a larger survey of our own (Evans, Rothfield, and Niederman, 1971), to be present in SLE patients as compared to controls.The present study expands our previous preliminary communication on the increase of the four virus antibodies in SLE as compared to control
Lipid nanoparticles for skin penetration enhancement—correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy
Authors: S. Lombardi Borgia, M. Regehly, R. Sivaramakrishnan, W. Mehnert, H.C. Korting, K. Danker, B. Röder, K.D. Kramer, M. Schäfer-Korting
Journal: Journal of Controlled Release (2005)
[616] BASELINE HCVRNA AND RAPID VIROLOGICAL DECAY ARE THE MAIN PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE IN HIV-HCV COINFECTED PATIENTS
Authors: L. Martin-Carbonero, M. Nunez, P. Barreiro, M. Romero, J. Garcia-Samaniego, J. Sola, M.A. Berdiin, I.I. Hernandez-Burruezo, M.J. Galindo, C. Miralles, B. Ramos, V. Soriano
Journal: Journal of Hepatology (2007)
Effects of omega-3 fatty acids on complement-mediated glomerular epithelial cell injury
Authors: D. Jordi Goldstein, David C. Wheeler, David J. Salant
Journal: Kidney International (1996)

To define the mechanisms by which fish oil protects rats with passive Heymann nephritis (PHN) from proteinuria in vivo, we investigated whether omega-3 fatty acid substitution of glomerular epithelial cells (GEC) in culture alters their susceptibility or response to complement-mediated sublethal injury. The results show that GECs can be cultured under conditions that effectively incorporate omega-3 or omega-6 fatty acids into membrane phospholipids without causing toxicity. Under these conditions, sublethal injury with anti-Fx1A and C5b-9 stimulated a 6.6-fold increase in TxA2 production by GECs substituted with arachidonic acid (AA, omega-6) but no increase was detected in eicosapentaenoic acid (EPA, omega-3) substituted cells. Sublethal cell membrane injury was of equal severity in both groups as measured by the release of preloaded biscarboxyethyl carboxyfluorescein and by the transepithelial flux of albumin. In addition, omega-3 and omega-6 fatty acid substituted cells showed similar increases in diacylglycerol mass in response to sublethal injury by C5b-9, suggesting that omega-3 incorporation did not limit phospholipid (PL) hydrolysis by PLC. From this we can conclude that the protective effect of fish oil in PHN does not appear to result from the preservation of GEC integrity but is likely related to changes in the production of lipid mediators.
What Is Wrong With Discharges Against Medical Advice (and How to Fix Them)
Authors: David Alfandre, John Henning Schumann
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of fluorodeoxyglucose positron emmission tomograpy and nonfluoroscopic electroanatomical mapping in myocardial viability assessment
Authors: Mariann Gyonayosi, Senta Graf, Dietmar Glogar, Aliashgar Khorsand, Christian Pirich, Heinz Sochor, Gerold Porenta
Journal: Journal of the American College of Cardiology (2002)
Inhibition of T helper 2 chemokine production by narrowband ultraviolet B in cultured keratinocytes
Authors: R. Hino, M. Kobayashi, T. Mori, H. Orimo, T. Shimauchi, K. Kabashima, Y. Tokura
Journal: British Journal of Dermatology (2007)

Narrowband ultraviolet B (NB-UVB) has recently been used for the treatment of various skin disorders. Its effects on the production of cytokines and chemokines by keratinocytes are unknown.To investigate the effect of NB-UVB on production of chemokines and proinflammatory cytokines by keratinocytes in comparison with broadband (BB)-UVB.Normal human epidermal keratinocytes (or the human keratinocyte cell line HaCaT in some experiments) at semiconfluency were irradiated with NB-UVB at 10, 100, 500 or 1000 mJ cm(-2) or BB-UVB at 10 or 100 mJ cm(-2). The cultures were maintained in the presence or absence of interferon (IFN)-gamma at 200 U mL(-1). The 72-h culture supernatants were analysed by enzyme-linked immunosorbent assay to quantify T helper (Th)1 chemokines (IFN-inducible protein 10 and monokine induced by IFN-gamma), Th2 chemokines [macrophage-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC)] and proinflammatory cytokines [interleukin (IL)-1alpha and tumour necrosis factor (TNF)-alpha]. The expression of mRNA for these molecules was simultaneously assessed by reverse transcriptase-polymerase chain reaction. The culture supernatants were also tested for their chemotactic activity for Th1 and Th2 cells. The two UVB sources were compared on the basis of their minimal erythemal doses and clinically used doses.Although both NB-UVB and BB-UVB increased the production of IL-1alpha and TNF-alpha, the augmentative effect of NB-UVB was less than that of BB-UVB. Both wavelength ranges of UVB enhanced or had no effect on Th1 chemokine production, but suppressed the production of Th2 chemokines MDC and TARC. This was confirmed by chemotactic assay, which showed decreased chemotactic activity for Th2 cells by the culture supernatants from NB-UVB-irradiated keratinocytes.NB-UVB reduces the production of Th2 chemokines without excess production of proinflammatory cytokines, suggesting its therapeutic effectiveness on Th2-mediated skin disorders as well as its relative safety in clinical usage.
Hepatocellular carcinoma (HCC): Can it still be considered acontroversial indication for liver transplantation (LT)?
Authors: D. Nicolás, M. Berenguer, M. Pastor, V. Aguilera, V. Ortiz, A. Mova, M. Prieto, F. San Juan, D. Carrasco, J. Mir, J. Berenguer
Journal: Journal of Hepatology (2000)
Dobutamine stress echocardiography identifies hibernating myocardium and predicts recovery of left ventricular function after coronary revascularization.
Authors: C G Cigarroa, C R deFilippi, M E Brickner, L G Alvarez, M A Wait, P A Grayburn
Journal: Circulation (1993)

The identification of hibernating myocardium is important in selecting patients who will benefit from coronary revascularization. This study was performed to determine whether dobutamine stress echocardiography (DSE) could identify hibernating myocardium and predict improvement in regional systolic wall thickening after revascularization.DSE was performed in 49 consecutive patients with multivessel coronary disease and depressed left ventricular function. Contractile reverse during DSE was defined by the presence of two criteria: (1) improved systolic wall thickening in at least two adjacent abnormal segments and (2) > or = 20% improvement in regional wall thickening score. Postoperative echocardiograms were evaluated for improved regional wall thickening in 25 patients at least 4 weeks after successful coronary revascularization. All studies were read in blinded fashion. Contractile reserve during DSE was present in 24 (49%) of 49 patients. The presence or absence of contractile reserve on preoperative DSE predicted recovery of ventricular function in the 25 patients who underwent successful revascularization. Thus, 9 of 11 patients with contractile reserve had improved systolic wall thickening after revascularization (hibernating myocardium), whereas 12 of 14 patients without contractile reserve did not improve (P = .003).Dobutamine stress echocardiography provides a simple, cost-effective, and widely available method of identifying hibernating myocardium and predicting improvement in regional left ventricular wall thickening after coronary revascularization. This technique may be clinically valuable in the selection of patients for coronary revascularization.
Trends in US Emergency Department Visits
Authors: Margaret Kirkegaard
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE TREATMENT OF THE ACUTE PSYCHOSES IN PRIVATE PRACTICE.
Authors: C. EUGENE RIGGS
Journal: JAMA (1901)

The various forms of mental perversion usually first come under the observation of the general practitioner As for the acute insanities, their prognosis varies in proportion to their early recognition and treatment Skilful attention at the outset will frequently [ill] an attack, or, at least, cause to run a benign and favorable course that which would otherwise have developed into a prolonged and serious illness. "In regarding the causation of insanity," says Dr. Mercier, "we should not exclusively concentrate attention upon the nervous system, but should remember that this is a question of general medicine. We must not wrap ourselves up too closely in our specialty; we should take wide views, and regard insanity as a malady, not of the brain alone, but of the whole man; it is a disease of the whole organism and it can only be properly understood and properly dealt with when so regarded." Since
Successful treatment of a patient with postpartum factor VIII inhibitor with recombinant human interferon α 2a
Authors: R. Schwerdtfeger, G. Hintz, D. Huhn
Journal: American Journal of Hematology (1991)

Abstract A patient who had developed a postpartum inhibitor to factor VIII and who did not respond to repeated therapy with steroid and high‐dose intravenous gammaglobulin G was treated with one short course of low‐dose recombinant interferon α 2a (rhlFN) s.c. Within 7 weeks from the start of rhlFN treatment, the inhibitor disappeared. It remains undetectable 8 months after therapy.
TCT-34 The appearance of jailed side branches post-procedure, at 6, 12, 24 and 36 months following implantation of bioresorbable vascular devices - Insights from the ABSORB Cohort B trial using three-dimensional optical coherence tomography
Authors: Yoshinobu Onuma, Hector M. Garcia-Garcia, Jacques Koolen, Takashi Muramatsu, Shimpei Nakatani, John A. Ormiston, Patrick W. Serruys, Leif Thuesen, Robert J. Van Geuns, Robert J. Whitbourn, Stephan Windecker
Journal: Journal of the American College of Cardiology (2013)
Should We Expand the Pharyngitis Paradigm for Adolescents and Young Adults?
Authors: Robert M. Centor
Journal: Annals of Internal Medicine (2010)

Letters6 April 2010Should We Expand the Pharyngitis Paradigm for Adolescents and Young Adults?Robert M. Centor, MDRobert M. Centor, MDFrom University of Alabama at Birmingham, Huntsville, AL 35801.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-7-201004060-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Drs. De Meyere and Matthys presents a rationale for not changing the pharyngitis paradigm for adolescents and young adults. I disagree, but perhaps did not make my point clear enough.Our current paradigm focuses solely on whether patients have group A β-hemolytic streptococcal pharyngitis. I am suggesting that we expand the paradigm to also include F. necrophorum pharyngitis.What are the implications of a new paradigm? We who study pharyngitis have an obligation to learn more about F. necrophorum pharyngitis, to prevent the morbidity and mortality that can occur from that infection. Although we encourage early diagnosis of ...References1. Matthys J, De Meyere M, van Driel ML, De Sutter A. Differences among international pharyngitis guidelines: not just academic. Ann Fam Med. 2007;5:436-43. [PMID: 17893386] CrossrefMedlineGoogle Scholar2. Centor RM, Allison JJ, Cohen SJ. Pharyngitis management: defining the controversy. J Gen Intern Med. 2007;22:127-30. [PMID: 17351852] CrossrefMedlineGoogle Scholar3. Linder JA, Chan JC, Bates DW. Evaluation and treatment of pharyngitis in primary care practice: the difference between guidelines is largely academic. Arch Intern Med. 2006;166:1374-9. [PMID: 16832002] CrossrefMedlineGoogle Scholar4. Singh S, Dolan JG, Centor RM. Optimal management of adults with pharyngitis—a multi-criteria decision analysis. BMC Med Inform Decis Mak. 2006;6:14. [PMID: 16533386] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Robert M. Centor, MDAffiliations: From University of Alabama at Birmingham, Huntsville, AL 35801.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoExpand the Pharyngitis Paradigm for Adolescents and Young Adults Robert M. Centor Should We Expand the Pharyngitis Paradigm for Adolescents and Young Adults? Em. Marc De Meyere and Jan Matthys Metrics 6 April 2010Volume 152, Issue 7Page: 478KeywordsAdolescentsAntibioticsDecision analysisPatientsPharyngitisSigns and symptomsStreptococcal pharyngitisStreptococcusYoung adults ePublished: 6 April 2010 Issue Published: 6 April 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Estimated Automobile Accident Mortality
Authors: Alden W. Squires
Journal: JAMA (1968)

<h3>To the Editor:—</h3> I thoroughly agree with your comments on the "grisly pastime" of predicting the traffic fatality scores during forthcoming holiday weekends, in which the National Safety Council has long and apparently gleefully indulged. I have noted several times that the much publicized predictions and statistics for holiday weekends are not particularly different from those which apply to every day of the year.
Murray Archibald Jackson
Authors: J. Jackson
Journal: BMJ (2012)

<h3>Objectives</h3> Three large randomized clinical trials have shown a survival benefit for patients treated with intraperitoneal (IP) compared with intravenous chemotherapy for advanced stage epithelial ovarian cancer (EOC). However, the use of IP chemotherapy in recurrent EOC is controversial. The purpose of this study was to determine outcomes, completion rates, and frequency of complications in patients with platinum-sensitive recurrent EOC treated with IP chemotherapy. <h3>Methods</h3> A retrospective, single-institution analysis of women who received IP chemotherapy for recurrent EOC from January 2003 to April 2010 was conducted. Study patients were identified from the Tumor Registry and office records. Demographic factors, stage, histology, surgical findings, cytoreduction status, and subsequent therapies were abstracted. Progression-free (PFS) and overall survival (OS) were estimated by Kaplan-Meier methods. <h3>Results</h3> Fifty-six women who received IP chemotherapy for their first EOC recurrence were identified. The mean age of patients was 56.7 years (range, 40–79 y). Fifty-five patients (98.3%) had previously completed at least 6 cycles of intravenous chemotherapy. Of all patients, 87.5% were initially diagnosed with advanced stage disease (stage IIA–IV). All patients underwent secondary cytoreduction at the time of IP port placement. Moreover, 67.9% of patients were considered optimally cytoreduced (&lt;1 cm residual disease) at the end of the secondary debulking surgery. Forty-two patients (75%) were able to successfully complete at least 6 cycles of IP chemotherapy. Reasons for noncompletion were disease progression, allergic reaction, renal failure, pain, severe nausea and vomiting, death, and patient refusal. Six patients (10.7%) developed port complications including pain around port site, port malfunction, and port erosion into small bowel. Median PFS since the initiation of IP chemotherapy was 10.5 months (95% confidence interval, 7.5–16.4 months) and median OS was 51 months (95% confidence interval, 40.8–61.1 months). <h3>Conclusions</h3> Intraperitoneal chemotherapy is a feasible option for patients with recurrent EOC, with high completion rates, low frequency of complications, and acceptable PFS and OS.
Japanese encephalitis outbreak kills 1300 children in India
Authors: Ganapati Mudur
Journal: BMJ (2005)

An outbreak of Japanese encephalitis in the northern Indian state of Uttar Pradesh has killed more than 1300 children over the past four months. It has rekindled calls from public health specialists for more intensive efforts to prevent future outbreaks.

Since the first cases in the current outbreak were reported in August, Indian authorities have reported 6171 cases nation-wide, including 5700 cases and 1315 deaths in Uttar Pradesh alone.

“The outbreak in …
THE EFFECT OF ADRENOCORTICOTROPHIC HORMONE IN CONGENITAL ADRENAL HYPERPLASIA WITH VIRILISM AND IN CUSHING'S SYNDROME TREATED WITH METHYL TESTOSTERONE 1
Authors: Roger A. Lewis, Lawson Wilkins
Journal: Journal of Clinical Investigation (1949)

There have been several reports of the metabolic effects of adrenocorticotrophic hormone in normal individuals (1-3) and in patients with Addison's disease (1), or panhypopituitarism (4).This trophic hormone has little or no effect upon the metabolic processes in Addison's disease.In normal individuals and in cases of panhypopituitarism there may be profound effects.The changes which occur in the first four hours after a single injection of 25 mg.have been studied by Thorn and his coworkers (1).The hematological changes consist of a shift from mononuclear to polymorphonuclear cells and a fall in the number of eosinophils.The metabolic changes are reflected in the urinary excretion.Using creatinine as a reference there is a rise in uric acid, potassium, chloride and sodium.Browne and his group (2) have studied the ef- fect of large doses, 210 mg., of adrenocorticotrophic hormone administered over a 24-hour period to a normal patient.They found oliguria, weight gain, increased excretion of 17-ketosteroids and neutral reducing lipids, increased excretion of potassium and retention of sodium and chloride.The reten- tion of sodium was apparent during the 24 hours of treatment and more marked during the 24 hours immediately after treatment.There was also an increase in the fasting blood sugar from 98 to 148 mg.%o, glycosuria and a slight rise in the urinary output of nitrogen.The effect of long range treatment with adreno- corticotrophic hormone has been studied by Thorn and his group, 40 mg. a day for four to six days (1); by Mason et al., 25-100 mg. a day for 12
Effectiveness of Bicycle Safety Helmets in Preventing Serious Facial Injury
Authors: Diane C. Thompson
Journal: JAMA (1996)

<h3>Objective.</h3> —To assess the effectiveness of helmets in preventing facial injuries. <h3>Design.</h3> —Case-control study between March 1, 1992, and August 31, 1994. <h3>Setting.</h3> —Seven Seattle, Wash, area hospitals including the regional trauma center and a large staff-model health maintenance organization. <h3>Patients.</h3> —Cases were patients with serious facial injury, ie, fractures or lacerations; controls were patients who had injuries other than facial. Minor facial injuries were excluded to avoid ascertainment bias in those seeking care for serious injuries to other areas. <h3>Results.</h3> —Serious facial injuries occurred to 700 (20.7%) patients. Helmets were used by 47% of cases and 57% of controls. After adjusting for age, sex, speed, and surface, we found that helmets reduced the risk of injury to the upper face (odds ratio [OR], 0.36; 95% confidence interval [CI], 0.26-0.49) and middle face (OR, 0.35; 95% CI, 0.24-0.50) but had no significant effect on serious injury to the lower face (OR, 0.88; 95% CI, 0.72-1.07). <h3>Conclusions.</h3> —Bicycle helmets offer substantial protection for the upper and mid face in addition to their known protection against head injuries. Helmets do not appear to offer any protection for the lower face.